Results 191 to 200 of about 180,170 (299)

Real‐world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T‐cell therapy

British Journal of Haematology, EarlyView.
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann‐Haefelin, Gabriel Allo, Philipp Kasper   +11 more
wiley   +1 more source

The miR4261/PAMM axis in multiple myeloma promotes bone resorption. [PDF]

Sci Rep
Cui J, Bian S, Hao Z, Zhang X, Zhang C, Zhao Y, Zhang X, Wang H.   +7 more
europepmc   +1 more source

Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts

British Journal of Haematology, EarlyView.
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng, Pei Meng, Mathias Heldbo, Olafur Davidsson, Morten Munk Johansen, Sigrún Thorsteinsdóttir, Jojo Biel‐Nielsen Dietz, Ragnar Pétur Kristjansson, Ole Birger Vesterager Pedersen, Erik Sørensen, Christian Erikstrup, Christina Mikkelsen, Nanna Brøns, Henrik Ullum, Bitten Aagaard, Mie Topholm Bruun, Estrid Høgdall, DBDS Research Consortium, CHB Research Consortium, Bo Porse, Simon Husby, Sisse R. Ostrowski, Henrik Hjalgrim, Kirsten Grønbæk   +23 more
wiley   +1 more source

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas. [PDF]

Hemasphere
Stork M, Ondrouskova E, Mayerova J, Mareckova A, Porc JP, Reigl T, Mensikova K, Sendlerova N, Boichuk I, Cieslar J, Bilcikova M, Adam Z, Krejci M, Sandecka V, Knechtova Z, Jelinkova Z, Krticka M, Nekuda V, Rohan T, Hrabcakova V, Janska Vojtkova L, Borsky M, Radova L, Jarosova M, Pour L, Kotaskova J.   +25 more
europepmc   +1 more source

MULTIPLE MYELOMA [PDF]

BMJ, 1907
J R, Charles, H H, Sanguinetti
openaire   +2 more sources

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Pterostilbene in the Management and Treatment of Multiple Myeloma. [PDF]

Curr Issues Mol Biol
Buehrer BS, Grden AR, Johnson E, Patel MY, Raina R.   +4 more
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma. [PDF]

J Extracell Vesicles
De Coster M, Hyka L, De Cock S, Meeussen S, Wang Z, Tu C, Hernot S, Devoogdt N, David G, De Veirman K, Vanderkerken K, Menu E, Zimmermann P, De Bruyne E.   +13 more
europepmc   +1 more source

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

British Journal of Haematology, EarlyView.
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid   +2 more
wiley   +1 more source